• Demonstrated ability to move rapidly from idea to IND
• Five candidate products in the clinic and two declared pre-clinical programs
• Robust technology and IP foundation, including our TVE and manufacturing platforms
• Initial product safety and efficacy data substantiates the value of our platforms
• Opportunities to expand to other indications and modalities within genetic medicine
GENERAL SUMMARY:
\nReporting to the Sr. Vice President, Ophthalmology Therapeutic Area Head the VP Late Stage Ophthalmology provides strategic and operational leadership for the global development of ophthalmic genetic medicines in Late Stage Drug Development Phase.
\nWe seek an experienced physician to play a critical role in the build out and leading of the late stage Clinical Development Organization at 4DMT as we spearhead the introduction of the first intravitreally delivered genetic medicines for the treatment of the most common causes of irreversible blindness. The successful candidate will lead the late stage clinical development strategy and execution and clinical trial in late stage. A candidate for this role should also feel confident to attract and develop talent in their part of the organization as indications and the trial portfolio grow. The VP, Clinical Development will be the primary point person for medical oversight of clinical studies with responsibilities to include clinical trial design, protocol development, medical monitoring, review and interpretation of clinical trial data, drafting key clinical documents such as protocol, CSR, briefing package, IND, NDA, BLA, etc. This role will be responsible for timely execution of deliverables in close collaboration with relevant internal and external partners.
\nRESPONSIBILITIES:
\nQUALIFICATIONS:
\nEducation:
\nExperience:
\nSkills:
\nBase salary compensation range: $354,000 - $447,000
\nPlease note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.
\nFull-Time
Confirmed live in the last 24 hours
Develops gene therapies for genetic diseases
$354k - $447k/yr
Senior, Expert
Oakland, CA, USA
Get referrals →
You have ways to get a 4D Molecular Therapeutics referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 11 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
4D Molecular Therapeutics develops gene therapies to treat serious genetic diseases by delivering specific genetic material to patients' cells using adeno-associated virus (AAV) vectors. Their focus is on patients with genetic disorders like cystic fibrosis, and they operate in the biopharmaceutical market, emphasizing research, clinical trials, and eventual commercialization of their therapies. The company recently raised $75 million in Series C financing and secured $14 million from the Cystic Fibrosis Foundation to advance their gene therapy, 4D-710. 4DMT aims to lead in gene therapy development, ensuring effective treatments reach those in need.
Company Size
201-500
Company Stage
IPO
Headquarters
Emeryville, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
EMERYVILLE, Calif., March 28, 2024 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced an update on its regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for the treatment of CF lung disease.
Monday, 4D Molecular Therapeutics FDMT-5.21%+ Free Alerts released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.
4D Molecular Therapeutics announces proposed public offering of common stock.
4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) just released its quarterly report and things are looking bullish.
To address this, 4DMT launched a single safety study involving nonhuman primates to evaluate 4D-310 combined with an immunosuppressive regimen using rituximab and sirolimus (R/S) to lower the risk of aHUS and toxicity-related side effects.